Match tier
Listed
Presence
Current · Arkansas
Last published
2024
Sources
OpenAlex · ORCID
Refreshed
2026-08-08
Biography and Research Information
OverviewAI-generated summary
Otis M. Davis's research focuses on cardiovascular function and risk factors, particularly within the context of chronic kidney disease (CKD). His work investigates the pharmacological effects of antiplatelet medications, comparing the efficacy of ticagrelor and clopidogrel in patients with advanced CKD. Studies have examined how these drugs inhibit platelet aggregation and influence inflammatory markers. Additionally, his research explores the relationship between platelet count, platelet volume, and the progression of CKD. Davis has published four scholarly works, with a total of 16 citations and an h-index of 2. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Nishank Jain, Jerry Ware, Yasir Rahmatallah, and Adam Corken.
Metrics
- h-index: 2
- Publications: 4
- Citations: 19
Selected Publications
-
Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD] (2024)
-
Platelet Count and Platelet Volume in Patients with CKD (2023)
-
Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease (2023)
-
Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD (2022)
Collaboration Network
Top Collaborators
Nishank Jain
University of Arkansas for Medical Sciences
4 shared publications
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]
- Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD
John M. Arthur
Central Arkansas Veterans Healthcare System
2 shared publications
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
Jerry Ware
University of Arkansas for Medical Sciences
2 shared publications
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
Junqiang Dai
University of Kansas (US)
2 shared publications
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD
Adam Corken
University of Arkansas for Medical Sciences
1 shared publication
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
Narenraj Arulprakash
University of Arkansas for Medical Sciences
1 shared publication
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
Milind A. Phadnis
University of Kansas Medical Center (US)
1 shared publication
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
Yasir Rahmatallah
University of Arkansas for Medical Sciences
1 shared publication
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
J. L. Mehta
Central Arkansas Veterans Healthcare System
1 shared publication
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
S. Susan Hedayati
The University of Texas Southwestern Medical Center (US)
1 shared publication
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
Susan S. Smyth
Central Arkansas Veterans Healthcare System
1 shared publication
In database
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
Rajshekhar A. Kore
University of Arkansas for Medical Sciences
1 shared publication
In database
- Platelet Count and Platelet Volume in Patients with CKD
Alexandra M. Moore
University of Arkansas for Medical Sciences (US)
1 shared publication
- Platelet Count and Platelet Volume in Patients with CKD
Jawahar L. Mehta
Central Arkansas Veterans Healthcare System
1 shared publication
In database
- Platelet Count and Platelet Volume in Patients with CKD
Donald Lynch
University of Cincinnati (US)
1 shared publication
- Platelet Count and Platelet Volume in Patients with CKD
Similar Researchers
Based on overlapping research topics
Nishank Jain
University of Arkansas for Medical Sciences
Platelet Disorders and Treatments
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Vincz Ong
University of Arkansas for Medical Sciences
Platelet Disorders and Treatments
Cardiovascular Function and Risk Factors
Dialysis and Renal Disease Management
Adam Corken
University of Arkansas for Medical Sciences
Platelet Disorders and Treatments
Pharmacological Effects and Toxicity Studies
Dialysis and Renal Disease Management
N. Jain
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Dialysis and Renal Disease Management
R. Scicali
University of Arkansas for Medical Sciences
Platelet Disorders and Treatments
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Tong Mu
University of Arkansas – Fort Smith
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Immune Response and Inflammation